Formulation and clinical evaluation of hydrogel containing bisabolol nanocapsules for treatment of dermatitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200115046143N2

Enrollment

Registered

2021-06-25

Start date

2021-11-23

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eczema. Intrinsic (allergic) eczema

Interventions

Intervention 1: Intervention group: Intervention group: Topical Flucinolone cream 0.25% (Manufactured by Behvarzan Pharmaceutical Company) plus topical gel containing bisabolol nanocapsules (Manufactu

Eligibility

Sex/Gender

All

Age

12 Years to 65 Years

Inclusion criteria

Inclusion criteria: Chronic eczema of the hand

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Other concurrent skin lesions such as psoriasis Immunodeficiency

Design outcomes

Primary

Measure	Time frame
The severity of pruritus. Timepoint: Before the intervention and 2 and 6 weeks after the intervention. Method of measurement: By taking history.;The severity of skin lesions. Timepoint: Before the intervention and 2 and 6 weeks after the intervention. Method of measurement: By clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoma Karami

Hamedan University of Medical Sciences

homa1karami@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026